Results 101 to 110 of about 30,536 (239)

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

Molecular Oncology
Hypermethylation of tumor suppressor genes is a hallmark of leukemia. The hypomethylating agent decitabine covalently binds, and degrades DNA (cytosine‐5)‐methyltransferase 1 (DNMT1).
Luisa Brock, Lina Benzien, Sandra Lange, Maja Huehns, Alexandra Runge, Catrin Roolf, Anett Sekora, Gudrun Knuebel, Hugo Murua Escobar, Christian Junghanss, Anna Richter   +10 more
doaj   +1 more source

Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. [PDF]

PLoS ONE, 2014
Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established.
Xiao Li, Qiang Song, Yu Chen, Chunkang Chang, Dong Wu, Lingyun Wu, Jiying Su, Xi Zhang, Liyu Zhou, Luxi Song, Zheng Zhang, Feng Xu, Ming Hou   +12 more
doaj   +1 more source

Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer

Cancer Science, EarlyView.
The combination of cladribine and irradiation significantly suppressed the growth of DU145‐derived tumors compared with the DMSO plus irradiation group in the mouse model. In addition, it also elevated the percentage of γH2AX‐positive cells after irradiation.
Toshiki Oka, Koji Hatano, Shohei Katsuki, Tomohiro Kanaki, Shunsuke Inoguchi, Masaru Tani, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Yohei Okuda, Akinaru Yamamoto, Toshihiro Uemura, Gaku Yamamichi, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Keisuke Tamari, Bangzhong Lin, Akiyoshi Tani, Kazutake Tsujikawa, Yutaka Takahashi, Kazuhiko Ogawa, Shawn E. Lupold, Norio Nonomura   +26 more
wiley   +1 more source

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers [PDF]

, 2016
The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other ...
Buschbeck, Marcus, Diesch, Jeannine, Garz, Anne-Kathrin, Götze, Katharina S., Palau, Anna, Zwick, Anabel   +5 more
core   +2 more sources

Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis

Experimental Hematology & Oncology, 2020
Background The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carried out to compare the two agents.
Bingbing Wen, Weiwen You, Sitian Yang, Xin Du   +3 more
doaj   +1 more source

Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML) [PDF]

, 2015
Introduction: Among patients with acute myeloid leukemia (AML), the DACO-016 randomized study showed reduction in mortality for decitabine [Dacogen® (DAC), Eisai Inc., Woodcliff Lake, NJ, USA] compared with treatment choice (TC): at primary analysis the
De Porre, Peter, Diels, Joris, Güntert, Andreas, Lange, Ansgar, Tapprich, Christoph, Thilakarathne, Pushpike, Tomeczkowski, Jörg, Xiu, Liang   +7 more
core   +3 more sources

Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.

Journal of Clinical Oncology, 2019
PURPOSE Anti-programmed death-1 (PD-1) monotherapy induces a high response rate in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but complete remission (CR) is infrequently observed. As decitabine is known to boost T-cell function, we
J. Nie, Chunmeng Wang, Yang Liu, Qing-ming Yang, Q. Mei, Liang Dong, Xiang Li, Jiejie Liu, Wenjing Ku, Yan Zhang, Meixia Chen, Xiaojing An, Lu Shi, M. Brock, J. Bai, W. Han   +15 more
semanticscholar   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease

Cancer Management and Research, 2019
Qing Ya Wang,* Yuan Li,* Ze Yin Liang, Yue Yin, Wei Liu, Qian Wang, Yu Jun Dong, Yu Hua Sun, Wei Lin Xu, Han Yun Ren Department of Hematology, Peking University First Hospital, Peking University, Beijing, People’s Republic of China*These authors ...
Wang QY, Li Y, Liang ZY, Yin Y, Liu W, Wang Q, Dong YJ, Sun YH, Xu WL, Ren HY   +9 more
doaj  

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia

Clinical Case Reports, 2020
A case of an early‐relapsed high‐risk T‐ALL with high BCL‐2 expression on leukemic blasts was successfully treated with decitabine and venetoclax, achieving a CR. We suggest decitabine and venetoclax should be synergistic in BCL2‐positive ALL.
Elisabetta Zappone, Emanuele Cencini, Marzia Defina, Anna Sicuranza, Alessandro Gozzetti, Sara Ciofini, Donatella Raspadori, Bianca Mecacci, Monica Bocchia   +8 more
doaj   +1 more source